D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [ 3H]-raclopride

Synapse

Volumn 64, Issue 8, 2010, Pages 624-633

  Peng, Teng ^a   Zysk, John ^a   Dorff, Peter ^a   Elmore, Charles S ^a   Ström, Peter ^b   Malmquist, Jonas ^b   Ding, Min ^a   Tuke, David ^a   Werkheiser, Jennifer ^a   Widzowski, Dan ^a   Mrzljak, Ladislav ^a   Maier, Donna ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Aripiprazole; D2 receptor; Haloperidol; In vitro binding; In vivo receptor occupancy; MNPA; PHNO; Quinpirole; Raclopride

Indexed keywords

2 CH3 O N N PROPYLNORAPOMORPHINE H 3; ARIPIPRAZOLE; DEXTRO 4 PROPYL 9 HYDROXY NAPHTHOXAZINE H 3; DOPAMINE 2 RECEPTOR; HALOPERIDOL; QUINPIROLE; RACLOPRIDE H 3; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CORPUS STRIATUM; DOSE RESPONSE; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING;

ANIMALS; APOMORPHINE; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; MALE; OXAZINES; RACLOPRIDE; RATS; RATS, LONG-EVANS; RECEPTORS, DOPAMINE D2; RECEPTORS, G-PROTEIN-COUPLED;

EID: 77956458325     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20771     Document Type: Article

References (48)

1. 11C]-raclopride study with amphetamine. J Neurosci 27:3998-4003.
2. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. 2002. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389. (Pubitemid 34680462)
3. Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G. 2000. Efficacy of aripiprazole in psychotic disorders: Comparison with haloperidol and placebo. Eur Neuropsychopharmacol 10 (Suppl 3): S309-S310.
4. Cedarbaum JM, Clark M, Toy LH, Green-Parsons A. 1990. Sustained- release (+)-PHNO [MK-458(HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2-receptor agonist administered as long-acting formulation. Mov Disord 5:293-393.
5. 3H]propyl- norapomorphine to dopamine receptors in living mouse striatum: Occupancy by endogenous dopamine and guanosine triphosphate-free G protein. J Cereb Blood Flow Metab 22:596-604.
6. De Lean A, Kilpatrick BF, Caron MG. 1982. Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists. Mol Pharmacol 22:290-297.
7. De Leon A, Patel NC, Crismon ML. 2004. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666.
8. Farde L, Wissel FA, Hall H, Halldin C, Stone-Elander S, Sedvall G. 1987. No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 44:671-672.
9. Farde L, Wiesel FA, Halldin C, Sedvall G. 1988. Central D2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76. (Pubitemid 18018572)
10. 11C]-MNPA in cynomolgus monkey. Nucl Med Biol 32:353-360.
11. 11C]-MNPA. Synapse 63:378-389.
12. Freeman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G. 1993. Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther 268:417-426.
13. George SR, Watanabe M, DiPaolo T, Falardeau P, Labrie F, Seeman P. 1985. The functional state of the dopamine receptor in the anterior pituitary is in the high-affinity form. Endocrinology 117:690-698.
14. 11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97:1089-1103.
15. 11C]-(+)-PHNO PET study. Neuropsychopharmacology 34:1078-1086.
16. 11C]-(+)-PHNO. Arch Gen Psychiatry 66:606-615.
17. Hall H, Köhler C, Gawell L, Farde L, Sedvall G. 1988. Raclopride, a new selective ligand for the dopamine-D2 receptors. Prog Neuro-Psychophamacol Biol Psychiatry 12:559-568.
18. Halldin C, Gulyas B, Farde L. 2001. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr Pharm Des 7:1907-1929.
19. 11C]Propyl- norapomorphine: A positron-labeled dopamine agonist for PET imaging of D(2) receptors. Nucl Med Biol 27:533-539.
20. Jaskiw G, Bongiovanni R. 2004. Brain tyrosine depletion attenuates haloperidol-induced striatal dopamine release in vivo and augments haloperidol-induced catalepsy in the rat. Psychopharmacology 172:100-107. (Pubitemid 38299756)
21. Kenakin T. 1997. Differences between natural and recombinant G-protein coupled receptor systems with varying receptor/G-protein stoichiometry. Trends Pharmacol Sci 18:456-464.
22. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y. 1995. 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H) -quinolinone (OPC- 14597), a new putative antipsychotic drug with both presynaptic autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274:329-336.
23. 3H]-raclopride: A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34:2251-2259.
24. Lathi RA, Figur LM, Piercey MF, Ruppel PL, Evans DL. 1992. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein- coupled receptor: Utilization of receptor state binding affinities. Mol Pharmarcol 42:432-438.
25. Lawler CP, Prioleau C, Lewis M, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB. 1999. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor substypes. Neuropsychopharmacology 20:612-627.
26. 3 receptors: Effects of ions and guanine nucleotides. J Pharmacol Exp Ther 274:790-797.
27. Malmberg A, Mohell N, Hook B, Johansson A, Hacksell U, Nordvall G. 1998. Interactions of ligands and inactive conformations of the dopamine D2 receptor. Eur J Pharmarcol 346:299-307.
28. Malmquist J, Olofsson S, Ström P. 2007. The synthesis of tritiated (R)-2- methoxy-N-n-propyl-nor-apomorphine (MNPA). J Label Compd Radiopharm 50:1211-1214. (Pubitemid 351211390)
29. 11C](+)-PHNO. Neuroimage 31:T33.
30. 3H]-raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nucl Med Biol 35:11-17.
31. McCormick PN, Kapur S, Reckless G, Wilson AA. 2009. Ex vivo [(11)C]-(+)- PHNO binding is unchanged in animal models displaying increased high- affinity states of the D(2) receptor in vitro. Synapse 63:998-1009.
32. Meador-Woodruff JH. 1994. Update on dopamine receptors. Ann Clin Psychiatry 6:79-90.
33. 11C]-raclopride. Synapse 52:188-208.
34. 11C]- raclopride in baboons. J Pharmacol Exp Ther 315:80-90.
35. Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E. 2006. Dopamine (D(2/3)) receptor agonist positron emission tomograpphy radiotracer [(11C)]-(+)-PHNO is a D(3) receptor preferring agonist in vivo. Synapse 52:188-208.
36. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S. 2006. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: Comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31:1854-1863.
37. Parker C, Clarke K, Gee AD, Gee A, Rabiner E. 2006. In vitro characterization of the high affinity D2/D3 dopamine agonist (+)-PHNO. Neuroimage 31 (Suppl 2):T29.
38. Rabiner E, Raymond R, Diwan M, McCormick P, Wilson A, Nobrega J. 2007. D3 and D2 components of ex vivo regional (+)-PHNO brain binding in wild-type and knock-out mice. J Nucl Med 48 (Suppl 2):113P.
39. high receptors. Synapse 61:1013-1018.
40. Seeman P, Ulpian C, Larsen RD, Anderson PS. 1993. Dopamine receptors labelled by PHNO. Synapse 14:254-262.
41. High receptors. Synapse 58:122-128.
42. High dopamine receptors. Synapse 60:319-346.
43. 11C]- raclopride. Synapse 59:260-269.
44. Sokoloff P, Giros B, Martes MP, Bouthenet ML, Schwartz JC. 1990. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleotics. Nature 347:146-151. (Pubitemid 120028930)
45. 11C]-raclopride displacement and PET. Neurology 46:1430-1436.
46. 11C]-raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: Multiparametric PET studies combined with microdialysis analysis. Synapse 37:95-103.
47. 11C]-(+)-PHNO. Biol Psychiatry 59:389-394.
48. 11C]-(+)-4- propyl-3,4,4a,5,6,10b-hexahydro-2H-naphthol[1,2-b]oxazin- 9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48:4153-4160.